ScoreWhy is Gland Pharma Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate -6.65% of over the last 5 years
2
Flat results in Sep 25
- PBT LESS OI(Q) At Rs 199.76 cr has Fallen at -14.8% (vs previous 4Q average)
- DEBTORS TURNOVER RATIO(HY) Lowest at 0.37 times
3
With ROE of 8.3, it has a Expensive valuation with a 3 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -4.16%, its profits have risen by 14.3% ; the PEG ratio of the company is 2.6
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -4.16% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Gland Pharma for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Gland Pharma
-4.16%
-0.15
27.25%
Sensex
4.83%
0.41
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.87%
EBIT Growth (5y)
-6.65%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.14
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.57
Tax Ratio
33.26%
Dividend Payout Ratio
42.65%
Pledged Shares
0
Institutional Holding
40.54%
ROCE (avg)
22.73%
ROE (avg)
11.08%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
34
Price to Book Value
3.02
EV to EBIT
26.71
EV to EBITDA
19.03
EV to Capital Employed
3.69
EV to Sales
4.56
PEG Ratio
2.55
Dividend Yield
1.03%
ROCE (Latest)
13.82%
ROE (Latest)
8.27%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
PAT(Latest six months)
At Rs 399.16 cr has Grown at 29.90%
-4What is not working for the Company
PBT LESS OI(Q)
At Rs 199.76 cr has Fallen at -14.8% (vs previous 4Q average
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.37 times
Loading Valuation Snapshot...
Here's what is working for Gland Pharma
Profit After Tax (PAT) - Latest six months
At Rs 399.16 cr has Grown at 29.90%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Here's what is not working for Gland Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 199.76 cr has Fallen at -14.8% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 234.36 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Debtors Turnover Ratio- Half Yearly
Lowest at 0.37 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
Non Operating Income - Quarterly
Highest at Rs 84.16 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
